Hepion Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OQB
Black Global 5 LLC, Red Global 3, LLC, and Darin Feinstein have jointly filed a Schedule 13D, reporting beneficial ownership of 10,000,000 shares of Hepion Pharmaceuticals, Inc. common stock, representing 11.1% of the class.
OQB
Executive Chairman Vincent LoPriore and affiliated entities report a combined 21.46% beneficial ownership stake in Hepion Pharmaceuticals, Inc.